Q3 2018 Investor Conference Call

Tuesday, November 13, 2018
Start at approx. 2:00 p.m. CET (1:00 p.m. UTC)


Investor News November 13, 2018

Third quarter of 2018

Bayer: Good performance in a challenging environment, Group outlook confirmed

Group sales increase by 1.9 percent (Fx & portfolio adj.) to 9.905 billion euros / EBITDA before special items level year on year at 2.202 billion euros / Business performance at Pharmaceuticals remains strong / Consumer Health with increase in sales (Fx & portfolio adj.), while currency effects weigh on earnings / Crop Science posts substantial rise in sales and earnings due to acquisition - successful start to integration process / Sales and earnings of Animal Health decline following a strong second quarter / One-time gain (before taxes) of roughly 3.9 billion euros from divestments / Net income 2.886 billion euros / Core earnings per share 1.19 euros / Adjusted 2018 Group outlook confirmed


baumann

Werner Baumann

CEO of Bayer AG

Audio recording of the investor conference call

 

Audio file

You can also play the audio recording on your mobile device.

 

 

Presentation charts

nickl

Wolfgang Nickl

CFO of Bayer AG

Q3 2018 Analyst and Investor Briefing

Interim Report Third Quarter 2018 

Transcript

Q3 2018 All in One Package for Investors and Analysts 

Supplemental financial information ahead of Q3 2018 results (October 24, 2018)